<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01610778</url>
  </required_header>
  <id_info>
    <org_study_id>eki-541</org_study_id>
    <nct_id>NCT01610778</nct_id>
  </id_info>
  <brief_title>Effects of 5-Aminolevulinic Acid on Glucose Metabolism</brief_title>
  <official_title>A Randomized, Double-blind, Cross-over Study to Assess Efficacy of 5-Aminolevulinic Acid in Type 2 Diabetic Patients on Medication.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hiroshima University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SBI Pharmaceuticals Co, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hiroshima University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate efficacy of 5-aminolevulinic acid in subjects with type 2
      diabetes on medication.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting glucose level</measure>
    <time_frame>Every 4 weeks (Overall 36 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1c level</measure>
    <time_frame>Every 4 weeks (Overall 36 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycoalbumin level</measure>
    <time_frame>Every 4 weeks (Overall 36 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting insulin level</measure>
    <time_frame>Every 4 weeks (Overall 36 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1,5-AG level</measure>
    <time_frame>Every 4 weeks (Overall 36 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum C-peptide level</measure>
    <time_frame>Every 4 weeks (Overall 36 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-R</measure>
    <time_frame>Every 4 weeks (Overall 36 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Type 2 Diabetes on Medication</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>5-aminolevulinic acid phosphate</intervention_name>
    <arm_group_label>Supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetic patients on medication

          -  HbA1c ≤ 9.0% (as JDS values, which is equivalent to HbA1c ≤ 9.4% as NGSP values)

          -  On stable treatment of diabetes for at least the last 3 months

          -  With permission to attend the clinical trial from the primary doctor

        Exclusion Criteria:

          -  On insulin therapy

          -  BMI ≤ 18 kg/m2 or ≥ 30 kg/m2

          -  History of porphyria, hemochromatosis, or viral hepatitis

          -  Pregnant or nursing a child

          -  Heart disease

          -  Renal or hepatic dysfunction

          -  Participation in any clinical trial within 90 days of the commencement of the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hiroshima University</name>
      <address>
        <city>Hiroshima</city>
        <zip>7320814</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2012</study_first_submitted>
  <study_first_submitted_qc>May 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2012</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hiroshima University</investigator_affiliation>
    <investigator_full_name>Fumiko Higashikawa</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

